Krista Qualmann on Genetic Counseling and Testing for Patients with Cancer

Video

Krista Qualmann discusses hereditary cancer syndromes.

Krista Qualmann, MS, CGC, Memorial Hermann Mischer Neuroscience Institute at the Texas Medical Center and UTHealth, discusses hereditary cancer syndromes.

About 5% to 10% of cancers are caused by single-gene disorders. These hereditary cancer syndromes are most well-known for causing cancers such as breast cancer, ovarian cancer and endometrial cancer. They can also have a hand in colon cancer, brain tumors and melanoma.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
4 experts in this video
4 experts in this video
Image of a woman with light brown hair wearing glasses with a blue background
Image of a woman wearing glasses in front of a blue background
Image of a woman with glasses in front of a blue background
Image of a man in a suit smiling in front of an Oncology Nursing News background
Image of a woman wearing a patterned shirt in front of a dark blue background
Photo of a woman wearing a blazer in front of an Oncology Nursing News backdrop
3 experts in this video
3 experts in this video
Related Content
Graphic of endometrial cancer cells

Selinexor Maintenance Offers Durable Benefit in Advanced Endometrial Cancer

Jax DiEugenio
June 27th 2025
Article

In TP53 wild-type advanced or recurrent endometrial cancer, selinexor improved multiple time-to-event outcomes vs placebo.

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Lindsay Fischer
October 2nd 2023
Podcast

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

Image of icons representing different organs in a circle with the female reproductive system in the middle under a magnifying glass

Relacorilant Combo Sustains Ovarian Cancer Benefit Post Platinum Break

Chris Ryan
June 23rd 2025
Article

The combination of relacorilant and nab-paclitaxel improved survival in platinum-resistant ovarian cancer following a break from platinum-based chemo.

The Vitals

Jacki Garcia and Kristin Hendrickson on Navigating Patients Through Phase 0 Trials

Lindsay Fischer
July 15th 2023
Podcast

Jacki Garcia, RN, BSN, CNRN; and Kristin Hendrickson, BA, RN, discuss phase 0 trials and how they can help expedite the research process for brain cancer therapies.

Image of a person holding a model of the female reproductive system

Relacorilant Combo Boosts PFS in Resistant Ovarian Cancer

Gina Mauro
June 13th 2025
Article

Relacorilant plus nab-paclitaxel improved PFS and showed a trend toward longer OS in platinum-resistant ovarian cancer in ROSELLA.

Anatomical image of a person with a breast tumor

T-DXd PFS Benefit Significant Across HR+, HER2-Low Breast Cancer Mutations

Tim Cortese
June 11th 2025
Article

T-DXd led to an ORR of 59.4% vs 33.9% with chemo, regardless of biomarker status, in HR+, HER2-low metastatic breast cancer, per DESTINY-Breast06.